To validate these findings, we made use of BaF3 cells [37], a p53 defective cell line that has been widely used to study BCR-ABL function and to test the effects of anti-CML drugs [38]. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.